EG HPCP 03a
Alternative Names: EG-HPCP-03aLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Evergreen Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID-19 pneumonia
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in COVID-19 pneumonia in China (IM, Injection)
- 28 Jul 2023 Evergreen Therapeutics withdrew a phase-II trial in COVID-19 pneumonia in China (IM) prior to enrolment (NCT04561180)
- 08 Oct 2020 Evergreen Therapeutics plans a phase II trial for COVID-19 pneumonia in China (IM, Injection) (NCT04561180)